Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic review.
van Dyk M, Boylan C, Michelet R, Mc Laughlin AM, Kichenadasse G, May N, Ziesenitz V, Van Den Anker JN, Groenland SL, Huitema ADR, Steeghs N, Mikus G, Kloft C, Tapp H. van Dyk M, et al. Among authors: mc laughlin am. BMJ Open. 2022 Jan 3;12(1):e053308. doi: 10.1136/bmjopen-2021-053308. BMJ Open. 2022. PMID: 34980620 Free PMC article.
Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS.
Opitz P, Zimmermann S, Mc Laughlin AM, Müller L, Fuxius S, Illerhaus G, Scherf-Clavel O, Kloft C, Hempel G; ON-TARGET study consortium. Opitz P, et al. Among authors: mc laughlin am. J Pharm Biomed Anal. 2022 Nov 30;221:115033. doi: 10.1016/j.jpba.2022.115033. Epub 2022 Sep 8. J Pharm Biomed Anal. 2022. PMID: 36148722
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.
Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL; CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium. Mc Laughlin AM, et al. Clin Pharmacol Ther. 2024 Mar 18. doi: 10.1002/cpt.3238. Online ahead of print. Clin Pharmacol Ther. 2024. PMID: 38494911
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
Mc Laughlin AM, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland SL, Huitema ADR, Steeghs N, Müller L, Fuxius S, Illerhaus G, Joerger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, For The On-Target Study Consortium. Mc Laughlin AM, et al. Cancers (Basel). 2021 Dec 14;13(24):6281. doi: 10.3390/cancers13246281. Cancers (Basel). 2021. PMID: 34944899 Free PMC article.
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Colombo I, Koster KL, Holer L, Haefliger S, Rabaglio M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin AM, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Joerger M. Colombo I, et al. Among authors: mc laughlin am. Eur J Cancer. 2024 Apr;201:113588. doi: 10.1016/j.ejca.2024.113588. Epub 2024 Feb 2. Eur J Cancer. 2024. PMID: 38377773 Free article. Clinical Trial.